肺纤维化的异常糖化:机制,生物标志物和治疗机会
Deqiang Ma1, Xiaodong Li1, Fanjie Meng1
1Department of Thoracic Surgery II, Department of Lung Transplantation, Organ Transplantation Center, The First Hospital of Jilin University, Changchun, 130021, China.
Biochemical and biophysical research communications
|August 25, 2025
概括
蛋白质糖化在纤维化发展和进展中至关重要. 了解这些变化为抗纤维化疗法提供了新的目标,并改善了纤维化疾病的诊断.
科学领域:
- 生物化学
- 分子生物学
- 病理学
背景情况:
- 纤维化,过度的痕,导致器官功能障碍和显著的死亡率.
- 目前的纤维化治疗主要是缓解性治疗,强调需要新的治疗点.
- 表观遗传修饰,特别是转化后修饰 (PTMs),在纤维化病变中越来越多地被识别出来.
研究的目的:
- 审查蛋白质糖化在肺纤维化中的作用.
- 探索纤维化疾病进展中的糖化模式和酶变化.
- 讨论基于糖化酶的生物标志物和纤维病理疗法的潜力.
主要方法:
- 对纤维化中的糖化最新文献的综述.
- 糖组和糖蛋白组数据的分析.
- 专注于肺纤维化模型和临床观察.
主要成果:
- 糖化对纤维化的开始和进展有显著影响.
- 特定的糖化模式和酶变化与纤维化疾病有关.
- 葡萄糖化学/葡萄糖蛋白化学的进步提高了对葡萄糖化作用的理解.
结论:
- 蛋白质糖化是纤维化疾病的关键因素,特别是肺纤维化.
- 基于糖化酶的生物标志物有望改善临床诊断.
- 针对糖化途径为纤维化提供了潜在的治疗策略.
相关概念视频
Proteoglycans
4.0K
Glycans, a class of complex heterogeneous molecules, can be covalently attached to proteins to form glycosylated proteins that regulate various physiological and pathological processes. Glycosylated proteins or glycoproteins comprise N-linked and O-linked oligosaccharides. O-glycosylation is the most common type of protein glycosylation. Here, glycans attach to the oxygen atom of the hydroxyl groups of Serine or Threonine residues. O-linked glycosylation occurs later in protein processing,...
4.0K
Pulmonary Hypertension: Classification and Pathogenesis
285
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
285
Cystic Fibrosis: Management
223
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
Sinus disease and chronic...
223


